Inspire Medical Faces Investor Lawsuit Over Inspire V Launch as Lead Plaintiff Deadline Nears

Plaintiffs say executives overstated commercial readiness for Inspire V, concealing operational setbacks that undercut early adoption.

Overview

The securities class action is pending in the U.S. District Court for the District of Minnesota and covers purchases from August 6, 2024 through August 4, 2025.
Investors have until January 5, 2026 to seek appointment as lead plaintiff, and multiple investor-rights firms are soliciting clients while emphasizing that no class has been certified.
The complaint alleges Medicare claims-processing software for Inspire V was not effective until July 1, 2025, limiting implanting centers’ ability to bill and slowing adoption.
Plaintiffs also cite a surplus of the prior Inspire IV device, incomplete training and onboarding at treatment centers, and weaker-than-touted demand for the new system.
On August 4, 2025 the company cut 2025 EPS guidance by more than 80% and the stock fell $42.04, or 32.4%, according to the filings.